News and Trends 22 Oct 2025 Deal after deal: Novartis spends billions in 2025 Novartis has been on a shopping spree of late. Find out about the pharma giant’s latest deals of 2025. October 22, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Oct 2025 Five latest advancements in Tourette’s syndrome research Discover recent Tourette’s syndrome research, highlighting emerging therapies and biotech advances in this neurological disorder. October 20, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Oct 2025 Biotech in Luxembourg: five companies that have made their name As the biotech industry in Luxembourg gradually grows, let us take a look at five biotech companies that are flourishing in the field. October 15, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 14 Oct 2025 Prader Willi syndrome: five much-anticipated therapies poised for approval The treatment drug to address insatiable hunger in people with Prader-Willi syndrome was greenlit this year. Discover five therapies in line for approval. October 14, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2025 Top biotech deals in September 2025 Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals were signed. October 8, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Oct 2025 Six companies leading the mRNA revolution in biotechnology Here are six mRNA biotechs that have raised funds in recent years to push their candidates ahead through preclinical and clinical trials. October 7, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2025 Merck backs out of Britain: is the U.K. struggling to retain its life sciences sector? Merck’s decision to back out of its $1 billion expansion comes as U.K. investments in life sciences declines. October 1, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2025 First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? FDA approval for Stealth BioTherapeutics’ elamipretide has been a long time coming. What does this mean for other ultra-rare disease companies? September 29, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 24 Sep 2025 Resurrecting the dodo: an ethical dilemma or chance at restoring biodiversity? Colossal Biosciences has just had a major breakthrough in its attempt to revive the dodo bird. What are the ethical concerns? September 24, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2025 Paper mills are a network: scientific fraud growing rapidly A new study has uncovered a network of paper mills contributing towards scientific fraud and disinformation. September 22, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2025 GLP-1 drugs on WHO Essential Medicines List: what’s the impact? The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision. September 19, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 17 Sep 2025 Budget blues: where are cell and gene therapies heading? The European Cell & Gene Therapy Summit 2025 was a hotspot for scientists and investors to discuss critical issues faced by the industry. September 17, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email